U.S. Markets open in 3 hrs 11 mins

Roche Holding AG (RHHBF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
257.300.00 (0.00%)
At close: 9:30AM EDT
People also watch
RHHVFRHHBYSNYNFNSRGFNVSEF
  • S
    Scott
    Scott

    RHHBY has been in a definite holding pattern for quite some time. They are an undisputed leader on both biotech and diagnostics, which gives it a distinct advantage as medicine becomes more personal in the years to come. RHHBY is also a leader in the immuno-oncology space, which doesn't get nearly the play as some other companies in the space. Just look at their pipeline: http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm

    While the stock price movement has been unimpressive recently, I continue to believe their leadership position and robust pipeline (especially immuno-oncology) will lead to significant stock gains in the years to come. I think the current $31ish price is a good price to start or add to a position. My average price is right around $28 and I'm planning on buying more in the coming days (likely adding 25% to my existing position.

    Please don't expect this to triple or even double in short order, as it already has a $200B+ market cap. Know what you're buying and treat the holding accordingly. Best of luck RHHBY longs.

    Pipeline
    www.roche.com
  • D
    Dana
    Dana
    owning this stock is like watching paint dry. (Should I stay or should I go?)
  • c
    chieu
    chieu
    FDA APPROVED ADMS
  • J
    Jane
    Jane
    Charles A. Henriques
    NeurogesX Inc.15% owner. QUTENZA developer - Non-Opioid Pain Therapies For Unmet Needs In Neuropathic Pain
    Neuropathic Pain Investor Sacred Heart University Fairfield CT BS/BA Business Administration
    San Francisco Bay Area 8,868 Connections Top AAA Profile Linkedin

    Charles A. Henriques increased stake in NeurogesX, Inc. Filed SC 13G/A form with U.S. Securities and Exchange Commission on February 13, 2017. Amount beneficially owned: 4,966,649 NGSX shares. CUSIP# 641252101.

    Form 13G is used when the filer owns between 5% and 20% of the company and plans to hold it only as a passive investor. If the filler intend to exert control and if the stake’s size exceeds 20%, then a 13D must be filed. Therefore, activist investors and practices such as: hostile takeovers, company breakups, and other “change of control” events, are not permitted by 13G filers.

    NeurogesX Inc. (NeurogesX), is a specialty pharmaceutical company focused on developing and commercializing a portfolio of novel non-opioid, Pain Management Therapies to address unmet medical needs. Qutenza the Company’s first commercial product, has FDA approval, available in USA by Acorda Therapeutics Inc. EU approval in 2009 and available at Astellas Pharma in all 28 European countries.

    Qutenza is a dermal delivery system designed to topically administer capsaicin to treat certain neuropathic pain conditions. Approved by the FDA for the management of neuropathic pain associated with postherpetic neuralgia (PHN). In September 2015, the European Commission approved a label extension for Qutenza to include diabetic patients with neuropathic pain, adding more value to product.
  • M
    Mike
    Mike

    https://seekingalpha.com/article/4101914-roche-almost-finish-line

    Roche Is Almost At The Finish Line
    Two Phase 3 studies provide the basis for FDA approval. The market opportunity for the Hemophilia Market is expected to grow in the billions. Many competitors i
    seekingalpha.com
  • R
    Ricoriki
    Ricoriki

    http://jcharlesassets.com/opiant-pharmaceuticals/?s=RHHBF has an alert for $RHHBF. Did anyone happen to see it as well? Looking for some good positive information from the company! Investing day trading. "rht"

    Best MicroCap, Small Cap and Emerging Stocks to Buy - J Charles Assets
    We search for the smart new growing companies to invest in with stock deals to watch in pharmacuetical and digital verticals.
    jcharlesassets.com
  • C
    Clevertrade
    Clevertrade
    Is it correct, that ROCHE will leave Switzerland end of 2017?
  • s
    seaghdha
    seaghdha

    Find tomorrow’s biggest stars today, ExplosiveOTC delivers insightful reports detailing the potential of hidden gems. www.explosiveotc.com

    ExplosiveOTC
    ExplosiveOTC
    www.explosiveotc.com
  • C
    Chad
    Chad

    http://wefunder.com/bchi/?s=RHHVF has an alert for $RHHVF. Did anyone happen to see it as well? Looking for some good positive information from the company! Investing day trading. "rht"

    Invest in Buying Collective Holdings Inc. | Organic, non-GMO foods at wholesale prices, delivered to your doorstep on @wefunder
    We're focused on (1) building the Buying Collective of CLEAN food shoppers through the Health Merchant® network; (2) sourcing CLEAN foods at the lowest possible cost; and (3) selling CLEAN foods with direct, free delivery to households that are part
    wefunder.com
  • B
    Bio
    Bio
    Charles A. Henriques
    NeurogesX Inc.15% owner. QUTENZA developer - Non-Opioid Pain Therapies For Unmet Needs In Neuropathic Pain

    Neuropathic Pain Investor Sacred Heart University Fairfield CT BS/BA Business Administration

    San Francisco Bay Area 500+ 500+757 connections linkedin.com

    Charles A. Henriques increased stake in NeurogesX, Inc. Filed SC 13G/A form with U.S. Securities and Exchange Commission on February 13, 2017. Amount beneficially owned: 4,966,649 NGSX shares. CUSIP# 641252101.

    Form 13G is used when the filer owns between 5% and 20% of the company and plans to hold it only as a passive investor. If the filler intend to exert control and if the stake’s size exceeds 20%, then a 13D must be filed. Therefore, activist investors and practices such as: hostile takeovers, company breakups, and other “change of control” events, are not permitted by 13G filers.

    NeurogesX Inc. (NeurogesX), is a specialty pharmaceutical company focused on developing and commercializing a portfolio of novel non-opioid, Pain Management Therapies to address unmet medical needs. Qutenza the Company’s first commercial product, has FDA approval, available in USA by Acorda Therapeutics Inc. EU approval in 2009 and available at Astellas Pharma in all 28 European countries.

    Qutenza is a dermal delivery system designed to topically administer capsaicin to treat certain neuropathic pain conditions. Approved by the FDA for the management of neuropathic pain associated with postherpetic neuralgia (PHN). In September 2015, the European Commission approved a label extension for Qutenza to include diabetic patients with neuropathic pain, adding more value to product.

    QUTENZA has a Patented Synthetic Capsaicin that works faster and better than Lyrica according to a study published in the European Journal of Pain, funded by Astellas Pharma Europe Ltd,

    Lyrica is Pfizer’s top selling drug with annual worldwide sales of over $5 billion.

    Grunenthal News 12 -12 -17 Acquiring Commercialization Rights for Qutenza® From Astellas.

    The Grünenthal Group is an independent, family-owned, international research-based pharmaceutical company headquartered in Aachen,
  • m
    mamacitaof8kidsandlookinggoodyoucanttouchthat
    mamacitaof8kidsandlookinggoodyoucanttouchthat
    Did Rhhby pay its dividend on 4/22/17. I have not received the dividend yet
  • M
    Mary
    Mary
    When is the dividend day?3/17 is the ex-dividend day.
  • m
    mamacitaof8kidsandlookinggoodyoucanttouchthat
    mamacitaof8kidsandlookinggoodyoucanttouchthat
    Imagearchiemcphee
  • M
    Mary
    Mary
    I mean 3/15 is ex...
  • s
    stock
    stock
    Bioprinting advances from Aether and Nano Dimension
    The 3D bioprinting market is gaining momentum with several recently developments. Israeli PCB 3D printer and ink company Nano Dimension (NASDAQ: NNDM) has made a further advance with a new patent for 3D inkjet printing with living cells. And San Fran
    3dprintingindustry.com
  • C
    CrazyCanuck
    CrazyCanuck
    NBC right now for news on their MS rugs
  • X
    Xtian
    Xtian
    Let's see a breakthrough day today!
  • a
    aldine
    aldine

    https://www.ucsf.edu/news/2017/03/406296/new-multiple-sclerosis-drug-ocrelizumab-could-halt-disease

    New Multiple Sclerosis Drug, Backed by 40 Years of Research, Could Halt Disease
    A newly approved drug that is the first to reflect the current scientific understanding of multiple sclerosis is holding new hope for the hundreds of thousands Americans living with the disease. It also highlights the importance of clinician scientis
    www.ucsf.edu
  • J
    Joe
    Joe
    where s Carl Icahn when we need him? Need to break this company up. To do otherwise is costing shareholders $$$ hundreds millon lost
  • J
    Jim
    Jim

    Will Roche use this brand new revolutionary 3D bioprinter?

    3Dprint.com says Aether will "Absolutely transform the entire bioprinting market"

    https://3dprint.com/165599/aether-bioprinter-u-of-cambridge/

    First Beta Unit of the Aether 1 Bioprinter Ships to the University of Cambridge, Ready to "Absolutely Transform the Entire Bioprinting Market"
    About a year ago, a startup called Aether seemed to come right out of the ether, promising a bold new 3D bioprinter with more than 20 swappable extruders.
    3dprint.com